Prime Cabinet Secretary Musalia Mudavadi has lauded the work of Kenyan scientists Wycliffe Omwancha and Charles Otieno, two Kenyan scientists working at Yunigen who are developing a groundbreaking pediatric sickle cell treatment innovation.
During his visit to Morgantown in West Virginia, Musalia interacted with the ground pediatric sickle cell treatment innovation poised to transform millions of lives globally.
Mudavadi, having been impressed by the innovation, congratulated the inventors and encouraged Kenyans that they are not limited.
Mudavadi’s comments on the innovation
“‘No man is limited’ perfectly captures the spirit of Kenyans I met during my visit to Morgantown, West Virginia,” he stated.
“Led by Wycliffe Omwancha and Charles Otieno of Yunigen, these brilliant scientists are developing a groundbreaking pediatric sickle cell treatment, Scedam, set to transform the lives of millions of children globally. “
Mudavadi added that the groundbreaking pediatric sickle cell treatment is set to transform the lives of millions of children globally.
Also Read:Mudavadi Wonders Why Kenyans Are Still Hungry
Additionally, Mudavadi explainsed that the innovation shows how Kenyans are talented, determined and globally impacted.
“Their innovation is a testament to Kenya’s talent, determination, and global impact.”
Leaders present in the event
Musalia Mudavadi, who is in the US on an official visit, said that he interacted with West Virginia senators who joined him in celebrating this inspiring work.
Accompanying him were West Virginia Senators Jack Woodrum, Glenn Jeffries, Jay Taylor, Tom Takubo, and Kenya’s Ambassador to the US, David Kerich.
Yunigen is a US-based startup aimed to manufacture quality and affordable medications. The Company’s products target emerging markets where the cost of medications is high and plagued with challenges.
Also Read:Mudavadi Wonders How No Single Gen Z Was Jailed After Anti-Ruto Protests
About Yunigen
The drugmaker operates from West Virginia University Innovation Corp and has since acquired facilities making it capable of manufacturing oral solid-dose medication or capsules.
Charles Otieno serves as the Chief Medical Officer of Yunigen. He is a medic with over 24 years of experience and also serves as the startup’s CEO. Beyond scientific achievements, the startup is focused on its human impact by devising solutions aimed at improving and saving lives through innovation.
Its main pillar has been its focus on the vision that sickle cell disease no longer dictates the quality of life or the length of life for those born with it.
With over 240,000 children born in Africa each year, Yunigen aims to provide affordable medications and alleviate the burden of many households on the cintinent.
Follow our WhatsApp Channel and X Account for real-time news updates.
